US20200022696A1 - Post-Implantation Tension Adjustment in Cardiac Implants - Google Patents

Post-Implantation Tension Adjustment in Cardiac Implants Download PDF

Info

Publication number
US20200022696A1
US20200022696A1 US16/564,809 US201916564809A US2020022696A1 US 20200022696 A1 US20200022696 A1 US 20200022696A1 US 201916564809 A US201916564809 A US 201916564809A US 2020022696 A1 US2020022696 A1 US 2020022696A1
Authority
US
United States
Prior art keywords
coupling
tissue anchor
tissue
coupling element
site
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/564,809
Inventor
Paolo DENTI
Andrea Guidotti
Kevin LYNN
Idan Tobis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
4Tech Inc
Original Assignee
4Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4Tech Inc filed Critical 4Tech Inc
Priority to US16/564,809 priority Critical patent/US20200022696A1/en
Assigned to 4TECH INC. reassignment 4TECH INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GUIDOTTI, ANDREA, LYNN, KEVIN, TOBIS, IDAN, DENTI, Paolo
Publication of US20200022696A1 publication Critical patent/US20200022696A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/04Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
    • A61B17/0401Suture anchors, buttons or pledgets, i.e. means for attaching sutures to bone, cartilage or soft tissue; Instruments for applying or removing suture anchors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2442Annuloplasty rings or inserts for correcting the valve shape; Implants for improving the function of a native heart valve
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2442Annuloplasty rings or inserts for correcting the valve shape; Implants for improving the function of a native heart valve
    • A61F2/2445Annuloplasty rings in direct contact with the valve annulus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2442Annuloplasty rings or inserts for correcting the valve shape; Implants for improving the function of a native heart valve
    • A61F2/2454Means for preventing inversion of the valve leaflets, e.g. chordae tendineae prostheses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/848Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents having means for fixation to the vessel wall, e.g. barbs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A61F2/91Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
    • A61F2/915Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B2017/00743Type of operation; Specification of treatment sites
    • A61B2017/00778Operations on blood vessels
    • A61B2017/00783Valvuloplasty
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/04Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
    • A61B17/0401Suture anchors, buttons or pledgets, i.e. means for attaching sutures to bone, cartilage or soft tissue; Instruments for applying or removing suture anchors
    • A61B2017/0409Instruments for applying suture anchors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/04Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
    • A61B17/0401Suture anchors, buttons or pledgets, i.e. means for attaching sutures to bone, cartilage or soft tissue; Instruments for applying or removing suture anchors
    • A61B2017/0412Suture anchors, buttons or pledgets, i.e. means for attaching sutures to bone, cartilage or soft tissue; Instruments for applying or removing suture anchors having anchoring barbs or pins extending outwardly from suture anchor body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/04Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
    • A61B17/0401Suture anchors, buttons or pledgets, i.e. means for attaching sutures to bone, cartilage or soft tissue; Instruments for applying or removing suture anchors
    • A61B2017/0446Means for attaching and blocking the suture in the suture anchor
    • A61B2017/0461Means for attaching and blocking the suture in the suture anchor with features cooperating with special features on the suture, e.g. protrusions on the suture
    • A61B2017/0462One way system, i.e. also tensioning the suture
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/04Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
    • A61B17/0401Suture anchors, buttons or pledgets, i.e. means for attaching sutures to bone, cartilage or soft tissue; Instruments for applying or removing suture anchors
    • A61B2017/0464Suture anchors, buttons or pledgets, i.e. means for attaching sutures to bone, cartilage or soft tissue; Instruments for applying or removing suture anchors for soft tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/04Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
    • A61B2017/0496Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials for tensioning sutures

Definitions

  • the present invention relates generally to minimally-invasive valve repair, and more specifically to minimally-invasive methods for repairing the tricuspid valve.
  • Functional tricuspid regurgitation is governed by several pathophysiologic abnormalities such as tricuspid valve annular dilatation, annular shape, pulmonary hypertension, left or right ventricle dysfunction, right ventricle geometry, and leaflet tethering. Treatment options for FTR are primarily surgical.
  • U.S. Pat. No. 8,475,525 to Maisano et al. describes a method that includes implanting at least a first tissue-engaging element in a first portion of tissue in a vicinity of a heart valve of a patient, implanting at least a second tissue-engaging element in a portion of a blood vessel that is in contact with an atrium of a heart of the patient, and drawing at least a first leaflet of the valve toward at least a second leaflet of the valve by adjusting a distance between the portion of the blood vessel and the first portion of tissue in the vicinity of the heart valve of the patient.
  • a proximal end portion of a longitudinal member is shaped so as to define one or more engaging elements (e.g., hooks or barbs), which are coupleable with the struts of a stent member in order to maintain the tension applied to a longitudinal member for remodeling the tricuspid valve.
  • engaging elements e.g., hooks or barbs
  • Some applications of the present invention provide a method of treating a heart of a patient, such as to reduce tricuspid valve regurgitation.
  • the method includes implanting a first tissue anchor in cardiac tissue of the patient, and a second tissue anchor in the patient.
  • the first tissue anchor is attached to one or more tethers that are fixed to a coupling element.
  • the coupling element is coupled to a first coupling site of the second tissue anchor, thereby coupling the first tissue anchor to the second tissue anchor via the one or more tethers.
  • tension is increased between the first and the second tissue anchors by decoupling the coupling element from the first coupling site and coupling the coupling element to a second coupling site of the second tissue anchor.
  • a method of treating a heart of a patient including:
  • first tissue anchor in cardiac tissue of the patient, the first tissue anchor attached to one or more tethers that are fixed to a coupling element;
  • the one or more tethers are slack before increasing the tension.
  • the coupling element includes a hook.
  • the coupling element is shaped so as to define an opening, and coupling the coupling element to the first coupling site includes coupling the opening to the first coupling site.
  • the coupling element includes a loop, which is shaped to define the opening.
  • the second tissue anchor includes a stent that includes a plurality of struts, which define the first and the second coupling sites.
  • the first and the second coupling sites extend radially inward to facilitate the coupling of the coupling element to the first and the second coupling sites from within the stent.
  • one or more of the struts extend radially inward at the first and the second couplings sites to facilitate the coupling of the coupling element to the first and the second coupling sites from within the stent.
  • the second tissue anchor includes hooks at the first and the second coupling sites, respectively.
  • At least one of the struts is oriented axially along the stent, and the axially-oriented strut defines the first and the second coupling sites.
  • the first and the second coupling sites extend radially inward to facilitate the coupling of the coupling element to the first and the second coupling sites from within the stent.
  • the axially-oriented strut is wider than others of the struts so as to serve as a backbone for the stent.
  • increasing the tension includes increasing the tension after allowing at least one week for tissue growth on the first tissue anchor.
  • increasing the tension includes increasing the tension within two months after implanting the first tissue anchor.
  • the coupling element is a first coupling element
  • the one or more tethers are additionally fixed to a second coupling element
  • coupling the coupling element to the first coupling site includes coupling one or more of the first and the second coupling elements to a plurality of first coupling sites.
  • coupling the coupling element to the first coupling site includes coupling the coupling element to the first coupling site after implanting the first and the second tissue anchors.
  • coupling the coupling element to the first coupling site includes coupling the coupling element to the first coupling site before implanting the first and the second tissue anchors.
  • coupling the coupling element to the first coupling site includes coupling the coupling element to the first coupling site after implanting the first tissue anchor and before implanting the second tissue anchor.
  • the coupling element is coated with a tissue-growth-inhibiting coating.
  • the first and the second coupling sites are coated with a tissue-growth-inhibiting coating.
  • the first tissue anchor includes a helical tissue-anchoring element.
  • implanting the first tissue anchor includes implanting the first tissue anchor in the vicinity of the tricuspid valve of the patient.
  • implanting the second tissue anchor includes implanting the second tissue anchor in a blood vessel selected from the group consisting of: a superior vena cava (SVC), an inferior vena cava (IVC), and a coronary sinus.
  • SVC superior vena cava
  • IVC inferior vena cava
  • coronary sinus a blood vessel selected from the group consisting of: a superior vena cava (SVC), an inferior vena cava (IVC), and a coronary sinus.
  • a system for treating a heart of a patient including:
  • a first tissue anchor which is configured to be implanted in cardiac tissue of the patient
  • one or more tethers which are attached to the first tissue anchor and are fixed to the coupling element;
  • a second tissue anchor which is configured to be implanted in the patient, and which includes a stent that includes a plurality of struts, which define first and second coupling sites to which the coupling element is configured to be coupled so as to couple the first tissue anchor to the second tissue anchor via the one or more tethers, wherein the first and the second coupling sites extend radially inward to facilitate the coupling of the coupling element to the first and the second coupling sites from within the stent,
  • the coupling element is coupleable to the first coupling site, and thereafter decouplable from the first coupling site and couplable to the second coupling site so as to increase tension between the first and the second tissue anchors.
  • the coupling element is shaped so as to define an opening, which is configured to be coupled to the first and the second coupling sites.
  • the coupling element includes a loop, which is shaped to define the opening.
  • the second tissue anchor includes hooks at the first and the second coupling sites, respectively.
  • At least one of the struts is oriented axially along the stent, and the axially-oriented strut defines the first and the second coupling sites.
  • the axially-oriented strut is wider than others of the struts so as to serve as a backbone for the stent.
  • one or more of the struts extend radially inward at the first and the second couplings sites to facilitate the coupling of the coupling element to the first and the second coupling sites from within the stent.
  • the coupling element is a first coupling element
  • the system includes a second coupling element, which is fixed to the one or more tethers.
  • the coupling element is coated with a tissue-growth-inhibiting coating.
  • the first and the second coupling sites are coated with a tissue-growth-inhibiting coating.
  • the first tissue anchor includes a helical tissue-anchoring element.
  • FIGS. 1A-C are schematic illustrations of a method of treating a heart of a patient, in accordance with an application of the present invention.
  • FIGS. 2A-C are schematic illustrations of a method of treating a heart of a patient, in accordance with an application of the present invention.
  • FIGS. 1A-C and 2 A-C are schematic illustrations of methods of treating a heart 10 of a patient, in accordance with respective applications of the present invention.
  • the methods are performed to treat a tricuspid valve 20 , such as by reducing tricuspid valve regurgitation.
  • a first tissue anchor 30 is implanted in cardiac tissue of the patient, such as in the vicinity of tricuspid valve 20 .
  • First tissue anchor 30 is attached to one or more tethers 32 that are fixed to a coupling element 34 , such as a hook, as shown in FIG. 1A , or an opening, as shown in FIG. 1B .
  • coupling element 34 comprises a loop, which is shaped so as to define the opening (configuration not shown).
  • a coupling support structure 36 is provided, which comprises coupling element 34 and attaches coupling element 34 to the one or more tethers 32 .
  • a second tissue anchor 40 is implanted in the patient, either before or after implanting first tissue anchor 30 , such as in a superior vena cava (SVC) 42 , an inferior vena cava (IVC) 44 (as shown), and a coronary sinus 46 .
  • first and second tissue anchors 30 and 40 are implanted in a transcatheter procedure (typically endovascularly, such as percutaneously), via a catheter, such as described in the applications incorporated hereinbelow by reference.
  • the one or more tethers 32 comprise two tethers 32 that are coupled together in situ during the first stage of the implantation procedure, such as using techniques described in one or more of the applications incorporated by reference hereinbelow.
  • coupling element 34 is coupled to a first coupling site 50 of second tissue anchor 40 , thereby coupling first tissue anchor 30 to second tissue anchor 40 via the one or more tethers 32 .
  • Coupling element 34 may be coupled to first coupling site 50 either after or before implanting first and second tissue anchors 30 and 40 , or after implanting first tissue anchor 30 and before implanting second tissue anchor 40 .
  • the one or more tethers 32 are slack, i.e., do not apply tension between first and second tissue anchors 30 and 40 .
  • first tissue anchor 30 thereafter, during a second stage of the implantation procedure, typically after allowing at least 24 hours (e.g., at least one week, such as at least one month) for tissue growth (e.g., fibrous and/or endothelial tissue growth) on first tissue anchor 30 to strengthen anchoring of first tissue anchor 30 in the cardiac tissue, tension is increased between first and second tissue anchors 30 and 40 by decoupling coupling element 34 from first coupling site 50 and coupling coupling element 34 to a second coupling site 52 of second tissue anchor 40 (different from first coupling site 50 ). For some applications, the tension is increased within two months after implanting first tissue anchor 30 .
  • tissue growth e.g., fibrous and/or endothelial tissue growth
  • second coupling site 52 is farther from first tissue anchor 30 than first coupling site 50 is from first tissue anchor 30 .
  • application of the tension remodels tricuspid valve 20 , by drawing two or three of the leaflets together to enhance coaptation.
  • the procedure may optionally include subsequent stages (e.g., a third stage) after the second stage (e.g., at least 24 hours after the second stage), in which tension is further increased by decoupling coupling element from its current coupling site (e.g., coupling site 50 ) and coupling coupling element 34 to yet another coupling site (e.g., a third coupling site).
  • a tool 54 is introduced through the vasculature via a catheter 56 , and used to recapture coupling element 34 .
  • tool 54 may comprise a lasso 58 , which is used to engage a hook 60 of coupling element 34 .
  • the hook may extend radially inward into a lumen of second tissue anchor 40 in order to facilitate engagement by tool 54 (e.g., lasso 58 ) when tool 54 has been introduced into the lumen of second tissue anchor 40 .
  • second tissue anchor 40 comprises a stent 70 that comprises a plurality of struts 72 , which define first and second coupling sites 50 and 52 .
  • first and second coupling sites 50 and 52 extend radially inward (i.e., toward a central longitudinal axis of stent 70 ) to facilitate the coupling of coupling element 34 to first and second coupling sites 50 and 52 from within stent 70 .
  • FIGS. 1A-C and 2 A-C first and second coupling sites 50 and 52 extend radially inward (i.e., toward a central longitudinal axis of stent 70 ) to facilitate the coupling of coupling element 34 to first and second coupling sites 50 and 52 from within stent 70 .
  • one or more of struts 72 extend radially inward at first and second couplings sites 50 and 52 to facilitate the coupling of coupling element 34 to first and second coupling sites 50 and 52 from within stent 70 .
  • second tissue anchor 40 comprises hooks (which are optionally shaped as tabs, as shown in FIGS. 2A-C ) at first and second coupling sites 50 and 52 , respectively; the hooks, and thus first and second coupling sites 50 and 52 , extend radially inward (optionally, one or more of struts 72 (e.g., axially-oriented strut 74 , described immediately below) also extend radially inward).
  • At least one 74 of struts 72 is oriented axially along the stent, and axially-oriented strut 74 defines first and second coupling sites 50 and 52 .
  • axially-oriented strut 74 is wider than others of struts 72 so as to serve as a backbone for the stent. (Although not illustrated, this backbone may also be provided for the configuration shown in FIGS. 1A-C .)
  • first tissue anchor 30 comprises a helical tissue-anchoring element.
  • fibrous glue is applied to the tissue-coupling element to help secure the anchor in place and minimize detachment.
  • tissue-growth-enhancing coating is also applied to the tissue-coupling element.
  • coupling element 34 is a first coupling element 34
  • the one or more tethers 32 are additionally fixed to a second coupling element 78 , such as a hook, as shown in FIGS. 1A-C , or an opening, as shown in FIGS. 2A-C (or to more than two coupling elements, such as shown in FIGS. 2A-C );
  • coupling support structure 36 may comprise second coupling element 78 in addition to first coupling element 34 .
  • coupling coupling element 34 to first coupling site 50 comprises coupling one or more of first and second coupling elements 34 and 78 to a plurality of first coupling sites 50 .
  • Providing a plurality of coupling elements provides redundancy; in case one of the coupling elements does not catch on second tissue anchor 40 , another of the coupling elements may catch (or both may catch, as shown in the figures).
  • first and second coupling elements 34 and 78 are arranged along coupling support structure 36 , optionally at a distance apart that is the same as a distance between first and second coupling sites 50 and 52 , such that when first coupling element 34 is repositioned from first coupling site 50 to second coupling site, as described hereinabove with reference to FIGS. 1B-C and 2 B-C, second coupling element 78 is repositioned from a third coupling site 80 to first coupling site 50 , i.e., takes the coupling site vacated by first coupling element 34 .
  • coupling element 34 , first coupling site 50 , and/or second coupling site 52 are coated with a tissue-growth-inhibiting coating (e.g., silicone). Such coating may facilitate the decoupling of coupling element 34 from first coupling site 50 and/or the coupling of coupling element 34 to second coupling site 52 , as described hereinabove with reference to FIGS. 1B-C and 2 B-C.
  • a tissue-growth-inhibiting coating e.g., silicone

Abstract

A method of treating a heart of a patient is provided, including implanting a first tissue anchor in cardiac tissue of the patient, the first tissue anchor attached to one or more tethers that are fixed to a coupling element. A second tissue anchor is implanted in the patient. The coupling element is coupled to a first coupling site of the second tissue anchor, thereby coupling the first tissue anchor to the second tissue anchor via the one or more tethers. Thereafter, after allowing at least 24 hours for tissue growth on the first tissue anchor to strengthen anchoring of the first tissue anchor in the cardiac tissue, tension is increased between the first and the second tissue anchors by decoupling the coupling element from the first coupling site and coupling the coupling element to a second coupling site of the second tissue anchor. Other embodiments are also described.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • The present application is a continuation of U.S. Non-Provisional Application 15/903,619, filed on Feb. 23, 2018, which claims the benefit of U.S. Provisional Application 62/465,400, filed Mar. 1, 2017, which is assigned to the assignee of the present application and each is incorporated herein by reference in its entirety. The present application is related to an international application to Denti et al. filed on even date herewith, entitled, “Post-implantation tension adjustment in cardiac implants.”
  • FIELD OF THE APPLICATION
  • The present invention relates generally to minimally-invasive valve repair, and more specifically to minimally-invasive methods for repairing the tricuspid valve.
  • BACKGROUND OF THE APPLICATION
  • Functional tricuspid regurgitation (FTR) is governed by several pathophysiologic abnormalities such as tricuspid valve annular dilatation, annular shape, pulmonary hypertension, left or right ventricle dysfunction, right ventricle geometry, and leaflet tethering. Treatment options for FTR are primarily surgical.
  • U.S. Pat. No. 8,475,525 to Maisano et al. describes a method that includes implanting at least a first tissue-engaging element in a first portion of tissue in a vicinity of a heart valve of a patient, implanting at least a second tissue-engaging element in a portion of a blood vessel that is in contact with an atrium of a heart of the patient, and drawing at least a first leaflet of the valve toward at least a second leaflet of the valve by adjusting a distance between the portion of the blood vessel and the first portion of tissue in the vicinity of the heart valve of the patient. In one configuration, a proximal end portion of a longitudinal member is shaped so as to define one or more engaging elements (e.g., hooks or barbs), which are coupleable with the struts of a stent member in order to maintain the tension applied to a longitudinal member for remodeling the tricuspid valve.
  • SUMMARY OF THE APPLICATION
  • Some applications of the present invention provide a method of treating a heart of a patient, such as to reduce tricuspid valve regurgitation. The method includes implanting a first tissue anchor in cardiac tissue of the patient, and a second tissue anchor in the patient. The first tissue anchor is attached to one or more tethers that are fixed to a coupling element. The coupling element is coupled to a first coupling site of the second tissue anchor, thereby coupling the first tissue anchor to the second tissue anchor via the one or more tethers. Thereafter, after allowing at least 24 hours for tissue growth on the first tissue anchor to strengthen anchoring of the first tissue anchor in the cardiac tissue, tension is increased between the first and the second tissue anchors by decoupling the coupling element from the first coupling site and coupling the coupling element to a second coupling site of the second tissue anchor.
  • There is therefore provided, in accordance with an application of the present invention, a method of treating a heart of a patient, including:
  • implanting a first tissue anchor in cardiac tissue of the patient, the first tissue anchor attached to one or more tethers that are fixed to a coupling element;
  • implanting a second tissue anchor in the patient;
  • coupling the coupling element to a first coupling site of the second tissue anchor, thereby coupling the first tissue anchor to the second tissue anchor via the one or more tethers; and
  • thereafter, after allowing at least 24 hours for tissue growth on the first tissue anchor to strengthen anchoring of the first tissue anchor in the cardiac tissue, increasing tension between the first and the second tissue anchors by decoupling the coupling element from the first coupling site and coupling the coupling element to a second coupling site of the second tissue anchor.
  • For some applications, the one or more tethers are slack before increasing the tension.
  • For some applications, the coupling element includes a hook.
  • For some applications, the coupling element is shaped so as to define an opening, and coupling the coupling element to the first coupling site includes coupling the opening to the first coupling site. For some applications, the coupling element includes a loop, which is shaped to define the opening.
  • For some applications, the second tissue anchor includes a stent that includes a plurality of struts, which define the first and the second coupling sites. For some applications, the first and the second coupling sites extend radially inward to facilitate the coupling of the coupling element to the first and the second coupling sites from within the stent. For some applications, one or more of the struts extend radially inward at the first and the second couplings sites to facilitate the coupling of the coupling element to the first and the second coupling sites from within the stent. For some applications, the second tissue anchor includes hooks at the first and the second coupling sites, respectively.
  • For some applications, at least one of the struts is oriented axially along the stent, and the axially-oriented strut defines the first and the second coupling sites. For some applications, the first and the second coupling sites extend radially inward to facilitate the coupling of the coupling element to the first and the second coupling sites from within the stent. For some applications, the axially-oriented strut is wider than others of the struts so as to serve as a backbone for the stent.
  • For some applications, increasing the tension includes increasing the tension after allowing at least one week for tissue growth on the first tissue anchor.
  • For some applications, increasing the tension includes increasing the tension within two months after implanting the first tissue anchor.
  • For some applications, the coupling element is a first coupling element, and the one or more tethers are additionally fixed to a second coupling element, and coupling the coupling element to the first coupling site includes coupling one or more of the first and the second coupling elements to a plurality of first coupling sites.
  • For some applications, coupling the coupling element to the first coupling site includes coupling the coupling element to the first coupling site after implanting the first and the second tissue anchors.
  • For some applications, coupling the coupling element to the first coupling site includes coupling the coupling element to the first coupling site before implanting the first and the second tissue anchors.
  • For some applications, coupling the coupling element to the first coupling site includes coupling the coupling element to the first coupling site after implanting the first tissue anchor and before implanting the second tissue anchor.
  • For some applications, the coupling element is coated with a tissue-growth-inhibiting coating.
  • For some applications, the first and the second coupling sites are coated with a tissue-growth-inhibiting coating.
  • For some applications, the first tissue anchor includes a helical tissue-anchoring element.
  • For some applications, implanting the first tissue anchor includes implanting the first tissue anchor in the vicinity of the tricuspid valve of the patient.
  • For some applications, implanting the second tissue anchor includes implanting the second tissue anchor in a blood vessel selected from the group consisting of: a superior vena cava (SVC), an inferior vena cava (IVC), and a coronary sinus.
  • There is further provided, in accordance with an application of the present invention, a system for treating a heart of a patient, including:
  • a first tissue anchor, which is configured to be implanted in cardiac tissue of the patient;
  • a coupling element;
  • one or more tethers, which are attached to the first tissue anchor and are fixed to the coupling element; and
  • a second tissue anchor, which is configured to be implanted in the patient, and which includes a stent that includes a plurality of struts, which define first and second coupling sites to which the coupling element is configured to be coupled so as to couple the first tissue anchor to the second tissue anchor via the one or more tethers, wherein the first and the second coupling sites extend radially inward to facilitate the coupling of the coupling element to the first and the second coupling sites from within the stent,
  • wherein the coupling element is coupleable to the first coupling site, and thereafter decouplable from the first coupling site and couplable to the second coupling site so as to increase tension between the first and the second tissue anchors.
  • For some applications, the coupling element is shaped so as to define an opening, which is configured to be coupled to the first and the second coupling sites. For some applications, the coupling element includes a loop, which is shaped to define the opening.
  • For some applications, the second tissue anchor includes hooks at the first and the second coupling sites, respectively.
  • For some applications, at least one of the struts is oriented axially along the stent, and the axially-oriented strut defines the first and the second coupling sites. For some applications, the axially-oriented strut is wider than others of the struts so as to serve as a backbone for the stent.
  • For some applications, one or more of the struts extend radially inward at the first and the second couplings sites to facilitate the coupling of the coupling element to the first and the second coupling sites from within the stent.
  • For some applications, the coupling element is a first coupling element, and the system includes a second coupling element, which is fixed to the one or more tethers.
  • For some applications, the coupling element is coated with a tissue-growth-inhibiting coating.
  • For some applications, the first and the second coupling sites are coated with a tissue-growth-inhibiting coating.
  • For some applications, the first tissue anchor includes a helical tissue-anchoring element.
  • The present invention will be more fully understood from the following detailed description of embodiments thereof, taken together with the drawings, in which:
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIGS. 1A-C are schematic illustrations of a method of treating a heart of a patient, in accordance with an application of the present invention; and
  • FIGS. 2A-C are schematic illustrations of a method of treating a heart of a patient, in accordance with an application of the present invention.
  • DETAILED DESCRIPTION OF APPLICATIONS
  • FIGS. 1A-C and 2A-C are schematic illustrations of methods of treating a heart 10 of a patient, in accordance with respective applications of the present invention. For some applications, the methods are performed to treat a tricuspid valve 20, such as by reducing tricuspid valve regurgitation.
  • As shown in FIGS. 1A and 2A, during a first stage of an implantation procedure, a first tissue anchor 30 is implanted in cardiac tissue of the patient, such as in the vicinity of tricuspid valve 20. First tissue anchor 30 is attached to one or more tethers 32 that are fixed to a coupling element 34, such as a hook, as shown in FIG. 1A, or an opening, as shown in FIG. 1B. Optionally, coupling element 34 comprises a loop, which is shaped so as to define the opening (configuration not shown). Optionally, a coupling support structure 36 is provided, which comprises coupling element 34 and attaches coupling element 34 to the one or more tethers 32. A second tissue anchor 40 is implanted in the patient, either before or after implanting first tissue anchor 30, such as in a superior vena cava (SVC) 42, an inferior vena cava (IVC) 44 (as shown), and a coronary sinus 46. Typically, first and second tissue anchors 30 and 40 are implanted in a transcatheter procedure (typically endovascularly, such as percutaneously), via a catheter, such as described in the applications incorporated hereinbelow by reference. Optionally, the one or more tethers 32 comprise two tethers 32 that are coupled together in situ during the first stage of the implantation procedure, such as using techniques described in one or more of the applications incorporated by reference hereinbelow.
  • Also as shown in FIGS. 1A and 2A, coupling element 34 is coupled to a first coupling site 50 of second tissue anchor 40, thereby coupling first tissue anchor 30 to second tissue anchor 40 via the one or more tethers 32. Coupling element 34 may be coupled to first coupling site 50 either after or before implanting first and second tissue anchors 30 and 40, or after implanting first tissue anchor 30 and before implanting second tissue anchor 40. For some applications, at this first stage of the implantation procedure, the one or more tethers 32 are slack, i.e., do not apply tension between first and second tissue anchors 30 and 40.
  • As shown in FIGS. 1B-C and 2B-C, thereafter, during a second stage of the implantation procedure, typically after allowing at least 24 hours (e.g., at least one week, such as at least one month) for tissue growth (e.g., fibrous and/or endothelial tissue growth) on first tissue anchor 30 to strengthen anchoring of first tissue anchor 30 in the cardiac tissue, tension is increased between first and second tissue anchors 30 and 40 by decoupling coupling element 34 from first coupling site 50 and coupling coupling element 34 to a second coupling site 52 of second tissue anchor 40 (different from first coupling site 50). For some applications, the tension is increased within two months after implanting first tissue anchor 30. Typically, second coupling site 52 is farther from first tissue anchor 30 than first coupling site 50 is from first tissue anchor 30. Typically, application of the tension remodels tricuspid valve 20, by drawing two or three of the leaflets together to enhance coaptation. The procedure may optionally include subsequent stages (e.g., a third stage) after the second stage (e.g., at least 24 hours after the second stage), in which tension is further increased by decoupling coupling element from its current coupling site (e.g., coupling site 50) and coupling coupling element 34 to yet another coupling site (e.g., a third coupling site).
  • Typically, in order to decouple coupling element 34 from first coupling site 50, during the second stage of the implantation procedure a tool 54 is introduced through the vasculature via a catheter 56, and used to recapture coupling element 34. For example, tool 54 may comprise a lasso 58, which is used to engage a hook 60 of coupling element 34. The hook may extend radially inward into a lumen of second tissue anchor 40 in order to facilitate engagement by tool 54 (e.g., lasso 58) when tool 54 has been introduced into the lumen of second tissue anchor 40.
  • For some applications, as shown in the figures, second tissue anchor 40 comprises a stent 70 that comprises a plurality of struts 72, which define first and second coupling sites 50 and 52. For some applications, such as shown in FIGS. 1A-C and 2A-C, first and second coupling sites 50 and 52 extend radially inward (i.e., toward a central longitudinal axis of stent 70) to facilitate the coupling of coupling element 34 to first and second coupling sites 50 and 52 from within stent 70. For some of these applications, such as shown in FIGS. 1A-C, one or more of struts 72 extend radially inward at first and second couplings sites 50 and 52 to facilitate the coupling of coupling element 34 to first and second coupling sites 50 and 52 from within stent 70. For others of these applications, such as shown in FIGS. 2A-C, second tissue anchor 40 comprises hooks (which are optionally shaped as tabs, as shown in FIGS. 2A-C) at first and second coupling sites 50 and 52, respectively; the hooks, and thus first and second coupling sites 50 and 52, extend radially inward (optionally, one or more of struts 72 (e.g., axially-oriented strut 74, described immediately below) also extend radially inward).
  • For some applications, at least one 74 of struts 72 is oriented axially along the stent, and axially-oriented strut 74 defines first and second coupling sites 50 and 52. Optionally, axially-oriented strut 74 is wider than others of struts 72 so as to serve as a backbone for the stent. (Although not illustrated, this backbone may also be provided for the configuration shown in FIGS. 1A-C.)
  • For some applications, first tissue anchor 30 comprises a helical tissue-anchoring element. For some applications, fibrous glue is applied to the tissue-coupling element to help secure the anchor in place and minimize detachment. Optionally, tissue-growth-enhancing coating is also applied to the tissue-coupling element.
  • For some applications, coupling element 34 is a first coupling element 34, and the one or more tethers 32 are additionally fixed to a second coupling element 78, such as a hook, as shown in FIGS. 1A-C, or an opening, as shown in FIGS. 2A-C (or to more than two coupling elements, such as shown in FIGS. 2A-C); for example, coupling support structure 36, if provided, may comprise second coupling element 78 in addition to first coupling element 34. For these applications, coupling coupling element 34 to first coupling site 50 comprises coupling one or more of first and second coupling elements 34 and 78 to a plurality of first coupling sites 50. Providing a plurality of coupling elements provides redundancy; in case one of the coupling elements does not catch on second tissue anchor 40, another of the coupling elements may catch (or both may catch, as shown in the figures).
  • For some applications, first and second coupling elements 34 and 78 are arranged along coupling support structure 36, optionally at a distance apart that is the same as a distance between first and second coupling sites 50 and 52, such that when first coupling element 34 is repositioned from first coupling site 50 to second coupling site, as described hereinabove with reference to FIGS. 1B-C and 2B-C, second coupling element 78 is repositioned from a third coupling site 80 to first coupling site 50, i.e., takes the coupling site vacated by first coupling element 34.
  • For some applications, coupling element 34, first coupling site 50, and/or second coupling site 52 are coated with a tissue-growth-inhibiting coating (e.g., silicone). Such coating may facilitate the decoupling of coupling element 34 from first coupling site 50 and/or the coupling of coupling element 34 to second coupling site 52, as described hereinabove with reference to FIGS. 1B-C and 2B-C.
  • The scope of the present invention includes embodiments described in the following applications, which are assigned to the assignee of the present application and are incorporated herein by reference. In an embodiment, techniques and apparatus described in one or more of the following applications are combined with techniques and apparatus described herein:
      • U.S. Pat. No. 8,475,525 to Maisano et al.;
      • U.S. Pat. No. 8,961,596 to Maisano et al.;
      • U.S. Pat. No. 8,961,594 to Maisano et al.;
      • PCT Publication WO 2011/089601;
      • U.S. Pat. No. 9,241,702 to Maisano et al.;
      • PCT Publication WO 2013/011502;
      • U.S. Provisional Application 61/750,427, filed Jan. 9, 2013;
      • U.S. Provisional Application 61/783,224, filed Mar. 14, 2013;
      • PCT Publication WO 2013/179295;
      • U.S. Provisional Application 61/897,491, filed Oct. 30, 2013;
      • U.S. Provisional Application 61/897,509, filed Oct. 30, 2013;
      • U.S. Pat. No. 9,307,980 to Gilmore et al.;
      • PCT Publication WO 2014/108903;
      • PCT Publication WO 2014/141239;
      • U.S. Provisional Application 62/014,397, filed Jun. 19, 2014;
      • PCT Publication WO 2015/063580;
      • US Patent Application Publication 2015/0119936;
      • U.S. Provisional Application 62/086,269, filed Dec. 2, 2014;
      • U.S. Provisional Application 62/131,636, filed Mar. 11, 2015;
      • U.S. Provisional Application 62/167,660, filed May 28, 2015;
      • PCT Publication WO 2015/193728;
      • PCT Publication WO 2016/087934;
      • US Patent Application Publication 2016/0242762;
      • PCT Publication WO 2016/189391;
      • US Patent Application Publication 2016/0262741; and
      • U.S. Provisional Application 62/376,685, filed Aug. 18, 2016.
  • It will be appreciated by persons skilled in the art that the present invention is not limited to what has been particularly shown and described hereinabove. Rather, the scope of the present invention includes both combinations and subcombinations of the various features described hereinabove, as well as variations and modifications thereof that are not in the prior art, which would occur to persons skilled in the art upon reading the foregoing description.

Claims (22)

1. A method of treating a heart of a patient, comprising:
implanting a first tissue anchor in cardiac tissue of the patient, the first tissue anchor attached to one or more tethers that are fixed to a coupling element;
implanting a second tissue anchor in the patient;
coupling the coupling element to a first coupling site of the second tissue anchor, thereby coupling the first tissue anchor to the second tissue anchor via the one or more tethers; and
thereafter, after allowing at least 24 hours for tissue growth on the first tissue anchor to strengthen anchoring of the first tissue anchor in the cardiac tissue, increasing tension between the first and the second tissue anchors by decoupling the coupling element from the first coupling site and coupling the coupling element to a second coupling site of the second tissue anchor.
2. The method according to claim 1, wherein the one or more tethers are slack before increasing the tension.
3. The method according to claim 1, wherein the coupling element comprises a hook.
4. The method according to claim 1, wherein the coupling element is shaped so as to define an opening, and wherein coupling the coupling element to the first coupling site comprises coupling the opening to the first coupling site.
5. The method according to claim 4, wherein the coupling element comprises a loop, which is shaped to define the opening.
6. The method according to claim 1, wherein the second tissue anchor comprises a stent that comprises a plurality of struts, which define the first and the second coupling sites.
7. The method according to claim 6, wherein the first and the second coupling sites extend radially inward to facilitate the coupling of the coupling element to the first and the second coupling sites from within the stent.
8. The method according to claim 7, wherein one or more of the struts extend radially inward at the first and the second couplings sites to facilitate the coupling of the coupling element to the first and the second coupling sites from within the stent.
9. The method according to claim 7, wherein the second tissue anchor comprises hooks at the first and the second coupling sites, respectively.
10. The method according to claim 6, wherein at least one of the struts is oriented axially along the stent, and the axially-oriented strut defines the first and the second coupling sites.
11. The method according to claim 10, wherein the first and the second coupling sites extend radially inward to facilitate the coupling of the coupling element to the first and the second coupling sites from within the stent.
12. (canceled)
13. The method according to claim 1, wherein increasing the tension comprises increasing the tension after allowing at least one week for tissue growth on the first tissue anchor.
14. The method according to claim 1, wherein increasing the tension comprises increasing the tension within two months after implanting the first tissue anchor.
15. The method according to claim 1, wherein the coupling element is a first coupling element, and the one or more tethers are additionally fixed to a second coupling element, and wherein coupling the coupling element to the first coupling site comprises coupling one or more of the first and the second coupling elements to a plurality of first coupling sites.
16. The method according to claim 1, wherein coupling the coupling element to the first coupling site comprises coupling the coupling element to the first coupling site after implanting the first and the second tissue anchors.
17. The method according to claim 1, wherein coupling the coupling element to the first coupling site comprises coupling the coupling element to the first coupling site before implanting the first and the second tissue anchors.
18. The method according to claim 1, wherein coupling the coupling element to the first coupling site comprises coupling the coupling element to the first coupling site after implanting the first tissue anchor and before implanting the second tissue anchor.
19-20. (canceled)
21. The method according to claim 1, wherein the first tissue anchor comprises a helical tissue-anchoring element.
22. The method according to claim 1, wherein implanting the first tissue anchor comprises implanting the first tissue anchor in the vicinity of the tricuspid valve of the patient.
23. The method according to claim 1, wherein implanting the second tissue anchor comprises implanting the second tissue anchor in a blood vessel selected from the group consisting of: a superior vena cava (SVC), an inferior vena cava (IVC), and a coronary sinus.
US16/564,809 2017-03-01 2019-09-09 Post-Implantation Tension Adjustment in Cardiac Implants Abandoned US20200022696A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/564,809 US20200022696A1 (en) 2017-03-01 2019-09-09 Post-Implantation Tension Adjustment in Cardiac Implants

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762465400P 2017-03-01 2017-03-01
US15/903,619 US10441266B2 (en) 2017-03-01 2018-02-23 Post-implantation tension adjustment in cardiac implants
US16/564,809 US20200022696A1 (en) 2017-03-01 2019-09-09 Post-Implantation Tension Adjustment in Cardiac Implants

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US15/903,619 Continuation US10441266B2 (en) 2017-03-01 2018-02-23 Post-implantation tension adjustment in cardiac implants

Publications (1)

Publication Number Publication Date
US20200022696A1 true US20200022696A1 (en) 2020-01-23

Family

ID=61599638

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/903,619 Expired - Fee Related US10441266B2 (en) 2017-03-01 2018-02-23 Post-implantation tension adjustment in cardiac implants
US16/564,809 Abandoned US20200022696A1 (en) 2017-03-01 2019-09-09 Post-Implantation Tension Adjustment in Cardiac Implants

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US15/903,619 Expired - Fee Related US10441266B2 (en) 2017-03-01 2018-02-23 Post-implantation tension adjustment in cardiac implants

Country Status (2)

Country Link
US (2) US10441266B2 (en)
WO (1) WO2018160456A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014141239A1 (en) * 2013-03-14 2014-09-18 4Tech Inc. Stent with tether interface
US11696828B2 (en) 2016-12-30 2023-07-11 Pipeline Medical Technologies, Inc. Method and apparatus for mitral valve chord repair
US11083580B2 (en) 2016-12-30 2021-08-10 Pipeline Medical Technologies, Inc. Method of securing a leaflet anchor to a mitral valve leaflet
US9877833B1 (en) 2016-12-30 2018-01-30 Pipeline Medical Technologies, Inc. Method and apparatus for transvascular implantation of neo chordae tendinae
US10925731B2 (en) 2016-12-30 2021-02-23 Pipeline Medical Technologies, Inc. Method and apparatus for transvascular implantation of neo chordae tendinae
WO2020139776A1 (en) 2018-12-24 2020-07-02 4Tech Inc. Self-locking tissue anchors
IT202000012562A1 (en) 2020-05-27 2021-11-27 Milano Politecnico DEVICE AND ASSEMBLY FOR REPAIRING A HEART VALVE

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3230858C2 (en) 1982-08-19 1985-01-24 Ahmadi, Ali, Dr. med., 7809 Denzlingen Ring prosthesis
ES2049653B1 (en) 1992-10-05 1994-12-16 Velazquez Francisco Farrer CORRECTIVE DEVICE FOR FEMALE URINARY INCONTINENCE.
AU9225598A (en) 1997-09-04 1999-03-22 Endocore, Inc. Artificial chordae replacement
US6752813B2 (en) 1999-04-09 2004-06-22 Evalve, Inc. Methods and devices for capturing and fixing leaflets in valve repair
ATE492219T1 (en) 1999-04-09 2011-01-15 Evalve Inc DEVICE FOR HEART VALVE OPERATION
US6997951B2 (en) * 1999-06-30 2006-02-14 Edwards Lifesciences Ag Method and device for treatment of mitral insufficiency
US8128698B2 (en) 1999-10-20 2012-03-06 Anulex Technologies, Inc. Method and apparatus for the treatment of the intervertebral disc annulus
US6616684B1 (en) 2000-10-06 2003-09-09 Myocor, Inc. Endovascular splinting devices and methods
US6997944B2 (en) 2001-08-13 2006-02-14 Advanced Cardiovascular Systems, Inc. Apparatus and method for decreasing stent gap size
WO2003016863A2 (en) * 2001-08-17 2003-02-27 United Chemical Technologies Apparatus for simultaneous processing of multiple samples
US20050177180A1 (en) 2001-11-28 2005-08-11 Aptus Endosystems, Inc. Devices, systems, and methods for supporting tissue and/or structures within a hollow body organ
US6764510B2 (en) 2002-01-09 2004-07-20 Myocor, Inc. Devices and methods for heart valve treatment
US8758372B2 (en) 2002-08-29 2014-06-24 St. Jude Medical, Cardiology Division, Inc. Implantable devices for controlling the size and shape of an anatomical structure or lumen
US7335213B1 (en) 2002-11-15 2008-02-26 Abbott Cardiovascular Systems Inc. Apparatus and methods for heart valve repair
US20040186566A1 (en) 2003-03-18 2004-09-23 Hindrichs Paul J. Body tissue remodeling methods and apparatus
US20060282161A1 (en) 2003-06-20 2006-12-14 Medtronic Vascular, Inc. Valve annulus reduction system
US7316706B2 (en) 2003-06-20 2008-01-08 Medtronic Vascular, Inc. Tensioning device, system, and method for treating mitral valve regurgitation
EP2526898B1 (en) 2003-12-23 2013-04-17 Sadra Medical, Inc. Repositionable heart valve
US20050177224A1 (en) 2004-02-11 2005-08-11 Fogarty Thomas J. Vascular fixation device and method
US7520720B2 (en) * 2004-07-28 2009-04-21 Sta-Rite Industries, Llc Pump
US7455681B2 (en) 2004-09-13 2008-11-25 Wound Care Technologies, Llc Wound closure product
US8608797B2 (en) 2005-03-17 2013-12-17 Valtech Cardio Ltd. Mitral valve treatment techniques
SE531468C2 (en) 2005-04-21 2009-04-14 Edwards Lifesciences Ag An apparatus for controlling blood flow
US7500989B2 (en) * 2005-06-03 2009-03-10 Edwards Lifesciences Corp. Devices and methods for percutaneous repair of the mitral valve via the coronary sinus
US9492277B2 (en) 2005-08-30 2016-11-15 Mayo Foundation For Medical Education And Research Soft body tissue remodeling methods and apparatus
US20070118151A1 (en) 2005-11-21 2007-05-24 The Brigham And Women's Hospital, Inc. Percutaneous cardiac valve repair with adjustable artificial chordae
WO2007100408A2 (en) 2005-12-15 2007-09-07 Georgia Tech Research Corporation Papillary muscle position control devices, systems & methods
US8932348B2 (en) * 2006-05-18 2015-01-13 Edwards Lifesciences Corporation Device and method for improving heart valve function
US20070282429A1 (en) 2006-06-01 2007-12-06 Hauser David L Prosthetic insert for improving heart valve function
US9131928B2 (en) 2007-12-20 2015-09-15 Mor Research Applications Ltd. Elongated body for deployment in a heart
US8382829B1 (en) 2008-03-10 2013-02-26 Mitralign, Inc. Method to reduce mitral regurgitation by cinching the commissure of the mitral valve
US20090276040A1 (en) * 2008-05-01 2009-11-05 Edwards Lifesciences Corporation Device and method for replacing mitral valve
US8808368B2 (en) 2008-12-22 2014-08-19 Valtech Cardio, Ltd. Implantation of repair chords in the heart
US20110011917A1 (en) 2008-12-31 2011-01-20 Hansen Medical, Inc. Methods, devices, and kits for treating valve prolapse
US20100217382A1 (en) 2009-02-25 2010-08-26 Edwards Lifesciences Mitral valve replacement with atrial anchoring
US9180007B2 (en) 2009-10-29 2015-11-10 Valtech Cardio, Ltd. Apparatus and method for guide-wire based advancement of an adjustable implant
US8475525B2 (en) 2010-01-22 2013-07-02 4Tech Inc. Tricuspid valve repair using tension
US9241702B2 (en) * 2010-01-22 2016-01-26 4Tech Inc. Method and apparatus for tricuspid valve repair using tension
US9307980B2 (en) * 2010-01-22 2016-04-12 4Tech Inc. Tricuspid valve repair using tension
US8961596B2 (en) 2010-01-22 2015-02-24 4Tech Inc. Method and apparatus for tricuspid valve repair using tension
WO2013021374A2 (en) * 2011-08-05 2013-02-14 Mitraltech Ltd. Techniques for percutaneous mitral valve replacement and sealing
US20140324164A1 (en) 2011-08-05 2014-10-30 Mitraltech Ltd. Techniques for percutaneous mitral valve replacement and sealing
US8900295B2 (en) * 2011-09-26 2014-12-02 Edwards Lifesciences Corporation Prosthetic valve with ventricular tethers
US8961594B2 (en) 2012-05-31 2015-02-24 4Tech Inc. Heart valve repair system
EP2943132B1 (en) 2013-01-09 2018-03-28 4Tech Inc. Soft tissue anchors
WO2014141239A1 (en) 2013-03-14 2014-09-18 4Tech Inc. Stent with tether interface
CA2917573A1 (en) 2013-07-11 2015-01-15 Shifamed Holdings, Llc Devices and methods for lung volume reduction
US10052095B2 (en) 2013-10-30 2018-08-21 4Tech Inc. Multiple anchoring-point tension system
US10022114B2 (en) 2013-10-30 2018-07-17 4Tech Inc. Percutaneous tether locking
US10039643B2 (en) 2013-10-30 2018-08-07 4Tech Inc. Multiple anchoring-point tension system
US9986993B2 (en) 2014-02-11 2018-06-05 Tendyne Holdings, Inc. Adjustable tether and epicardial pad system for prosthetic heart valve
US9801720B2 (en) 2014-06-19 2017-10-31 4Tech Inc. Cardiac tissue cinching
WO2016087934A1 (en) 2014-12-02 2016-06-09 4Tech Inc. Off-center tissue anchors
US10765539B2 (en) * 2015-05-27 2020-09-08 W. L. Gore & Associates, Inc. Stent graft device with anchoring members having adjustable geometries
WO2016189391A2 (en) 2015-05-28 2016-12-01 4Tech Inc. Off-center tissue anchors with tension members
US9592121B1 (en) * 2015-11-06 2017-03-14 Middle Peak Medical, Inc. Device, system, and method for transcatheter treatment of valvular regurgitation
JP6718189B2 (en) 2017-02-08 2020-07-08 4テック インコーポレイテッド Tensioning after implantation in heart implantation
CN111493925A (en) 2017-02-08 2020-08-07 4科技有限公司 Implanted dynamometer

Also Published As

Publication number Publication date
US10441266B2 (en) 2019-10-15
US20180249993A1 (en) 2018-09-06
WO2018160456A1 (en) 2018-09-07

Similar Documents

Publication Publication Date Title
US10441266B2 (en) Post-implantation tension adjustment in cardiac implants
US10682229B2 (en) Post-implantation tensioning in cardiac implants
US20220313424A1 (en) Platforms For Mitral Valve Replacement
US20210145580A1 (en) Post-implantation tensioning in cardiac implants
US20210000595A1 (en) Transcatheter valve devices and systems
US20180185179A1 (en) Stent with Tether Interfaces
US8357195B2 (en) Catheter based annuloplasty system and method
US20140074223A1 (en) Multiple Orifice Implantable Heart Valve and Methods of Implantation
US20070061010A1 (en) Device and method for reshaping mitral valve annulus
US20220192826A1 (en) Low profile prosthetic mitral valve
US20240016609A1 (en) Mitral valve implants
US20140155993A1 (en) Device for mitigating or preventing paravalvular leaks

Legal Events

Date Code Title Description
AS Assignment

Owner name: 4TECH INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DENTI, PAOLO;GUIDOTTI, ANDREA;LYNN, KEVIN;AND OTHERS;SIGNING DATES FROM 20170227 TO 20170425;REEL/FRAME:050330/0810

STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION